Breast cancer is a heterogeneous disease divided into three major subtypes with differing response to therapy: the hormone receptor-positive (with either estrogen receptor (ER) or progesterone receptor (PR) expression), the HER-2 amplified, and the triple-negative cancer (ER-negative, PR-negative and HER2-negative). This evidence concerns the gene ERBB2 and breast cancer.